Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model
Citations Over TimeTop 10% of 2015 papers
Abstract
Pre-eclampsia affects approximately 5% of all pregnant women and remains a major cause of maternal and fetal morbidity and mortality. The hypertension associated with pre-eclampsia develops during pregnancy and remits after delivery, suggesting that the placenta is the most likely origin of this disease. The pathophysiology involves insufficient trophoblast invasion, resulting in incomplete narrow placental spiral artery remodeling. Placental insufficiency, which limits the maternal-fetal exchange of gas and nutrients, leads to fetal intrauterine growth restriction. In this study, in our attempt to develop a new therapy for pre-eclampsia, we directly rescued placental and fetal hypoxia with nano-scale size artificial oxygen carriers (hemoglobin vesicles). The present study is the first to demonstrate that artificial oxygen carriers successfully treat placental hypoxia, decrease maternal plasma levels of anti-angiogenic proteins and ameliorate fetal growth restriction in the pre-eclampsia rat model.
Related Papers
- → Natural killer cells direct hemochorial placentation by regulating hypoxia-inducible factor dependent trophoblast lineage decisions(2011)169 cited
- → Trophoblast invasion and oxygenation of the placenta: measurements versus presumptions(2013)130 cited
- → Modeling Trophoblast Cell-Guided Uterine Spiral Artery Transformation in the Rat(2022)45 cited
- → Long non‑coding RNA NR_002794 is upregulated in pre‑eclampsia and regulates the proliferation, apoptosis and invasion of trophoblast cells(2019)19 cited
- → Recapitulation of Trophoblast Invasion During Pregnancy in a Physiological Hypoxia Induced Microfluidic Device(2019)2 cited